论文部分内容阅读
目的探讨HER-2/neu、增殖细胞核抗原(PCNA)在人膀胱移行细胞癌(BTCC)中的表达及临床意义。方法采用免疫组化技术检测58例BTCC组织、22例正常膀胱组织中HER-2/neu和PCNA的表达,分析HER-2/neu、PCNA表达率水平与肿瘤病理分级、临床分期的相关性,以及两指标间的相关性。结果HER-2/neu、PCNA在BTCC中的表达分别为53.4%、63.8%,明显高于正常膀胱黏膜。HER-2/neu在高分化、浅表性BTCC中的表达率分别为21.7%、29.0%,明显低于中低分化、浸润性BTCC。PCNA在高分化、表浅性BTCC中的表达率为30.4%、35.5%,明显低于中低分化、浸润性BTCC。HER-2/neu、PCNA在BTCC中的表达呈正相关。结论HER-2/neu促进BTCC的发生和发展,可作为诊断、评估恶性程度的指标。
Objective To investigate the expression of HER-2 / neu and proliferating cell nuclear antigen (PCNA) in human bladder transitional cell carcinoma (BTCC) and its clinical significance. Methods The expressions of HER-2 / neu and PCNA in 58 BTCC tissues and 22 normal bladder tissues were detected by immunohistochemistry. The correlation between the expression of HER-2 / neu and PCNA and the tumor grade and clinical stage were analyzed. As well as the correlation between the two indicators. Results The expressions of HER-2 / neu and PCNA in BTCC were 53.4% and 63.8%, respectively, which were significantly higher than those in normal bladder mucosa. The expression rates of HER-2 / neu in well differentiated and superficial BTCC were 21.7% and 29.0%, respectively, which were significantly lower than those in moderately and poorly differentiated invasive BTCC. The expression rate of PCNA in highly differentiated and superficial BTCC was 30.4% and 35.5%, which was significantly lower than that in moderately and poorly differentiated invasive BTCC. The expression of HER-2 / neu and PCNA in BTCC was positively correlated. Conclusion HER-2 / neu can promote the occurrence and development of BTCC, which can be used as an index to diagnose and evaluate the malignancy.